[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401652":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":32,"locations":39,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of Oxford","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-COVID",null,"We will enrol age, gender, BMI and co-morbidity matched non-COVID control subjects (no serological evidence of previous infection, or active\u002Fprevious symptoms suggestive of COVID-19). A minimum of 200 controls (as part of the COSMIC study) will be recruited.",[13],"Diagnostic Test: Magnetic Resonance Imaging",{"label":15,"type":10,"description":16,"interventionNames":17},"COVID-19","Hospitalised patients with moderate to severe infection (admitted for at least 2 days in hospital).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","Magnetic Resonance Imaging","We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.",[15,9],[25,26,27,28,29,30,31],"Cardiopulmonary exercise test","Spirometry","6 minute walk test","Questionnaires (mental health, cognitive assessment and quality of life)","Blood test","Transthoracic echocardiography (Sub-study)","CT lungs (Sub-study)",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Betty Raman, MBBS, DPhil, FRACP","CONTACT","01865234580","+44","betty.raman@cardiov.ox.ac.uk",[40],{"facility":5,"status":41,"city":42,"state":10,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Oxford","OX3 9DU","United Kingdom","UK",{"type":47,"coordinates":48},"Point",[49,50],-1.25596,51.75222,{"lat":50,"lon":49},[53,56,58,61],{"name":54,"role":35,"phone":55,"phoneExt":37,"email":38},"Betty Raman, MBBS, FRACP, DPhil","0186534580",{"name":57,"role":35,"phone":55,"phoneExt":37,"email":10},"Mark Cassar, MBBS",{"name":59,"role":60,"phone":10,"phoneExt":10,"email":10},"Stefan Neubauer, MD, FMedSCi","PRINCIPAL_INVESTIGATOR",{"name":34,"role":60,"phone":10,"phoneExt":10,"email":10},{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100401652","capturing-multiorgan-effects-of-covid-19-100401652",false,"NCT04510025","Capturing MultiORgan Effects of COVID-19","Assessing the Effects of Coronavirus Disease (COVID-19) on Multiple Organ Systems and Impact on Quality of Life, Functional Capacity and Mental Health","C-MORE","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 years or above.\n* Diagnosis of COVID-19 infection confirmed by detection of viral nucleic acid on reverse-transcription Polymerase Chain Reaction (RT-PCR).\n* Infection should be of moderate to severe intensity (i.e, patients with clinical signs of pneumonia such as respiratory rate \\> 30 breaths\u002Fmin; or severe respiratory distress; or SpO2 \\\u003C 90% (on room air) and admission for \\>48 hours.\n* Controls: Participants with no serological evidence of previous infection, or active\u002Fprevious symptoms suggestive of COVID-19, and who may or may not have comorbidities.\n\nExclusion Criteria:\n\n* Contraindication to MRI e.g. pregnancy, pacemaker, ferromagnetic implant, shrapnel injury, severe claustrophobia, inability to lie flat.\n* Any other significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study.\n* Any signs of active COVID-19 infection on day of visit.\n* Significantly impaired renal function (eGFR\\\u003C30 ml\u002Fmin)",true,"ALL","18 Years","100 Years",{"count":77,"type":78},750,"ESTIMATED","OBSERVATIONAL","The C-MORE study is prospective observational holistic longitudinal study which will characterise the prevalence of multi-organ injury among COVID-19 survivors post hospital discharge and assess its effects on quality of life, exercise tolerance and mental health.",[82,83],"Coronavirus Infection","Multi-Organ Disorder",[85,86,87,88,89],"Coronavirus disease","MRI","Multi-organ injury","Quality of Life","Mental Health","2025-02-04",{"date":92,"type":93},"2025-02-07","ACTUAL",{"date":95,"type":93},"2020-05-13",{"date":97,"type":78},"2026-05-01",{"name":5,"class":6},1]